Spectral AI, Inc. (MDAI) director John Michael DiMaio reported a direct award acquisition of 32,000 common shares on September 28, 2026. His directly held common shares following the transaction were 2,922,847. The reported price was a weighted average of $1.62 per share.
The reported equity holdings also include 250,000 non-qualified stock options, of which 100,000 were vested and the remaining 150,000 vest upon achievement of certain milestones, plus 100,000 restricted stock units: 50% vested on April 20, 2026, and 50% will vest on April 1, 2027.
John Michael DiMaio, a director of Spectral AI, Inc. (MDAI), acquired 60,000 common shares on September 23, 2026. The reported weighted-average price was $1.67 per share, and his direct holdings afterward were 2,890,847 shares.
The filing also lists direct ISO holdings covering 5,292 and 20,352 common shares, each at a $1.67 exercise price and expiring May 15, 2034. It lists NQSOs covering 250,000 shares at $1.25, expiring April 23, 2035; 100,000 were vested and 150,000 vest upon certain milestones. The 100,000 RSUs listed were 50% vested on April 20, 2026, with the remaining 50% to vest April 1, 2027.
Spectral AI, Inc. (MDAI) director John Michael DiMaio reported acquiring 21,012 shares of common stock on September 21, 2026 at a weighted average price of $1.69 per share and 10,988 shares on September 18, 2026 at a weighted average price of $1.61 per share, each as a grant or award acquisition. He also reports direct holdings of incentive stock options and non-qualified stock options over common stock, including options with exercise prices of $1.67 expiring May 15, 2034 and $1.25 expiring April 23, 2035, plus 100,000 restricted stock units tied to vesting dates in 2026 and 2027.
Spectral AI, Inc. (MDAI) announced that it has posted a new investor presentation outlining its DeepView AI-powered wound imaging platform and commercial plans. DeepView received FDA De Novo classification on May 21, 2026, authorizing U.S. commercial sales, and earlier obtained UKCA marking in February 2024.
The presentation highlights more than $250 million in non-dilutive government funding supporting development since 2013 and a $150 million BARDA Project BioShield contract, with $86 million committed to date and subsidies for the first 30 U.S. burn and trauma center system deployments. DeepView is described as detecting 88% of non-healing burns versus 42% for unaided burn physicians in cited studies.
Financial data show, as of June 30, 2026, cash of $14 million, total assets of $19 million, total liabilities of $31 million, and a stockholders' deficit of $12.1 million. Revenue was $29 million in 2024, $19 million in 2025, and $7 million in the first half of 2026, reflecting the shift from development funding toward commercial deployment.
Spectral AI, Inc. (MDAI) reported that director John Michael DiMaio received two equity awards of the company’s Common Stock, acquiring 22,000 shares on September 11, 2026 at a reported weighted average price of $1.59 per share and 10,000 shares on September 10, 2026 at a reported weighted average price of $1.56 per share, each described as a grant or award. The filing also lists outstanding equity incentives held directly by him, including fully vested incentive stock options over 5,292 and 20,352 shares at an exercise price of $1.67 expiring in 2034, non-qualified stock options over 250,000 shares at an exercise price of $1.25 expiring in 2035 (with 100,000 vested and 150,000 vesting upon milestone achievement), and 100,000 restricted stock units tied to Common Stock, half of which vested on April 20, 2026 and the remainder scheduled to vest on April 1, 2027.
Spectral AI, Inc. director John Michael DiMaio reported an acquisition of 35,000 shares of Common Stock on 2026-08-13 at a weighted average price of $1.64 per share, giving him 2,766,847 Common shares held directly after the transaction. The filing also lists existing equity incentives, including Incentive Stock Options exercisable for 5,292 and 20,352 Common shares at an exercise price of $1.67 expiring in 2034, 250,000 Non-Qualified Stock Options at $1.25 expiring in 2035 of which 100,000 were vested and 150,000 vest upon achievement of milestones, and 100,000 Restricted Stock Units tied to Common Stock, half of which vested on April 20, 2026, with the remaining half scheduled to vest on April 1, 2027.
LMR-affiliated investment entities reported a significant ownership position in Spectral AI, Inc. (MDAI). As of June 30, 2026, LMR Master Fund and LMR CCSA Master Fund together held warrants exercisable for 2,106,358 shares of Common Stock. These warrants represent approximately 6.2% of Spectral AI’s outstanding Common Stock, based on 31,823,985 shares outstanding as of May 29, 2026, plus shares that may be acquired within 60 days. The LMR Investment Managers share voting and dispositive power over these securities, with no sole voting or dispositive power reported for any individual Reporting Person.
Spectral AI, Inc. reported Q2 2026 research and development revenue of $3.5 million, down from $5.1 million, mainly due to lower reimbursed costs under its BARDA Project BioShield contract after FDA De Novo clearance of the DeepView® System and completion of an MTEC contract. Gross margin declined to 31.6% from 45.2%, reflecting cost-share provisions under the follow-on BARDA phase and lower margins on a fixed-fee contract.
Operating expenses rose 23.2% to $5.4 million, driven by higher stock-based compensation, increased selling and marketing ahead of first commercial sales, and higher non-revenue R&D. A favorable change in warrant liability helped total other income reach $0.3 million versus a prior-year expense of $(5.9) million, reducing Q2 net loss to $(4.2) million, or $(0.13) per share, from $(8.0) million, or $(0.31).
For YTD 2026, revenue was $7.5 million versus $11.8 million, with gross margin of 41.8%. Net loss was $(7.6) million compared to $(5.1) million, and Adjusted EBITDA was $(5.2) million versus $(2.4) million. Cash was $14.0 million at June 30, 2026, and the company reiterated full-year 2026 revenue guidance of approximately $18.5 million, primarily from continued DeepView development under BARDA.
Spectral AI, Inc. reported lower research and development revenue as it transitions from government-funded development toward commercialization of its DeepView System. Revenue was $3.5 million for the quarter and $7.5 million for the first half of 2026, down 30.4% and 36.2% from 2025, mainly due to reduced reimbursed costs under the PBS BARDA contract and cost-share provisions in the follow-on phase.
The company posted a quarterly net loss of $4.2 million and a year‑to‑date net loss of $7.6 million, with operating expenses rising on non‑reimbursed R&D, higher stock‑based compensation and commercialization spending. Cash and cash equivalents were $14.0 million and total debt $14.9 million, contributing to a stockholders’ deficit of $12.1 million. Management expects existing cash, the PBS BARDA contract and the Yorkville SEPA to fund operations for at least one year, but notes potential need for additional capital.
Strategically, the FDA granted De Novo classification for DeepView for burn indications on May 26 2026, allowing U.S. commercial distribution, with first sales expected by year‑end 2026 and U.K. commercialization following UKCA marking. BARDA accelerated $31.7 million of funding under the up‑to‑$150 million PBS contract, while a previously disclosed material weakness in internal control over financial reporting remains under remediation.
Spectral AI, Inc. has appointed Darcy Bajko as Chief Commercial Officer, effective July 31, 2026. She will lead commercial activities, including the global launch of the FDA De Novo–cleared DeepView® System for burn indication.
Her compensation includes a $315,000 annual salary, an annual target bonus of up to 30% of base pay, and stock options to acquire 150,000 common shares vesting over three years, with full vesting upon a change of control.